Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2016

View Archived Issues

Enumeral and Pieris sign definitive license agreement

First clinical data reported for anti-CD47 monoclonal antibody Hu5F9-G4

Novartis initiates phase II trial of CLR-325 in chronic stable heart failure

Millendo Therapeutics begins phase II trial on ATR-101

Enanta Pharmaceuticals patents FXR agonists

European Commission approves Avastin plus Tarceva for advanced NSCLC with EGFR-activating mutations

Mochida Pharmaceutical discloses OX2 receptor antagonists

Oncothyreon changes name to Cascadian Therapeutics

Crispr Therapeutics and Anagenesis Biotechnologies enter collaboration for P2MC technology

Merck Patent presents IRAK inhibitors

Phase II trial of erenumab in chronic migraine prevention meets primary endpoint

Fibrocell Science reports negative results for phase II trial evaluating Azficel-T

Korea Institute of Science and Technology reports development of protein kinase inhibitors

Bayer Schering Pharma describes IRAK-4 inhibitors

FDA advisory committees recommend approval of Pfizer's ALO-02

Phase I results of BI-860585 for the treatment of solid tumors

Regorafenib administered to pediatric patients with solid tumors in phase I study

Update of clinical trials for cancer vaccine NY-ESO-1(c259) SPEAR T cells given at ASCO

FDA grants fast track designation to Remedy's Cirara

Theravance Biopharma and Takeda Pharmaceutical enter agreement for TD-8954

Galderma advances trifarotene program for lamellar ichthyosis

Ultragenyx and Takeda enter partnership to develop and commercialize rare genetic disease therapies

European Commission grants orphan drug designation to XLRP gene therapy candidate

PuriCore holds pre-IND meeting with FDA for PR-022 in atopic dermatitis

Activin-A inhibitor shows promise for the treatment of granulosa cell ovarian cancer

Aspen gains ex-U.S. commercialization rights to AstraZeneca's anesthetic portfolio

Phase III data for first expected trastuzumab biosimilar MYL-1401O

Capmatinib-gefitinib combination shows promise in EGFR-mutant/c-Met+ non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...